TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12854076

Group type: EXPERIMENTAL
Intervention: CM235 gp120 (25, 50, or 100 microg)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: SF2 gp120 (0, 25, or 50 microg)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Combination of CM235 and SF2 gp120 vaccines
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 10097029

Group type: EXPERIMENTAL
Intervention: 1 hour routine exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (non-exercising students)
Number of subjects: 21
Study: 8548508

Group type: COMPARATOR
Intervention: H-reflex facilitation during response period
Number of subjects: 40

Group type: COMPARATOR
Intervention: Achilles tendon reflex facilitation during response period
Number of subjects: 40
Study: 2016618

Group type: EXPERIMENTAL
Intervention: Chlorambucil (30 mg/m2 orally day 1) and Prednisone (80 mg orally days 1 to 5) administered every 2 weeks (C + P)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cyclophosphamide (300 mg/m2 orally days 1 to 5), Vincristine (1.4 mg/m2 intravenously [IV] day 1), and Prednisone (100 mg/m2 orally days 1 to 5) given every 3 weeks (CVP)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Chlorambucil and Prednisone (C + P)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cyclophosphamide, Vincristine, and Prednisone (CVP)
Number of subjects: 122
Study: 7036711

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30856691

Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supragingival Scaling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no periodontal treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 60
Study: 29912799

Group type: EXPERIMENTAL
Intervention: Aripiprazole (5-15 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 27344828

Group type: EXPERIMENTAL
Intervention: Float needle therapy combined with reperfusion activity
Number of subjects: 35

Group type: COMPARATOR
Intervention: Simple float needle therapy
Number of subjects: 35
Study: 24939425

Group type: EXPERIMENTAL
Intervention: Coinfusion of low-dose GLP-1 and glucagon
Number of subjects: 13

Group type: COMPARATOR
Intervention: GLP-1 alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Glucagon alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Coinfusion of GLP-1 and glucagon
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: GLP-1 with glucagon
Number of subjects: 13
Study: 22063233

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 93

Group type: COMPARATOR
Intervention: Compression stockings
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene bypass
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Autologous bypass
Number of subjects: 93
Study: 20502467

Group type: EXPERIMENTAL
Intervention: Nutritional support prescribed to patients with overt malnutrition (n=191)
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Monitoring of weight during hospital stay
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: BMI calculation
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Nutritional Risk Screening 2002 tool
Number of subjects: 1583
Study: 17561350

Group type: EXPERIMENTAL
Intervention: Taxane treatment arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anthracycline-based regimens
Number of subjects: 0
Study: 16205932

Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 20 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12029208

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for severity scores
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement on overall impression for Alzheimer's pattern
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement on overall impression for heterogeneous pattern
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for overall impression for Alzheimer's pattern
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for overall impression for heterogeneous and normal patterns
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inter-observer agreement as reflected in percent agreement
Number of subjects: 48
Study: 12885182

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 mcg/kg (group F)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fentanyl 10 mcg/kg plus etomidate 0.2 mg/kg (group EF)
Number of subjects: 26
Study: 9654535

Group type: EXPERIMENTAL
Intervention: 100 mg of lamivudine
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 25 mg of lamivudine
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 8135383

Group type: EXPERIMENTAL
Intervention: LMA insertion with cuff partially inflated
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 2% lidocaine topical solution
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard deflated method
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: K-Y sterile lubricating jelly
Number of subjects: 122

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 122
Study: 2800985

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Saline containing mepivacaine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Saline containing bupivacaine
Number of subjects: 36
Study: 105441

Group type: EXPERIMENTAL
Intervention: Superfractionation treatment
Number of subjects: 602

Group type: COMPARATOR
Intervention: Standard fractionation schemes
Number of subjects: 602
Study: 30589514

Group type: EXPERIMENTAL
Intervention: ERAS pathway with ketorolac and pregabalin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard of care plus placebo
Number of subjects: 62
Study: 28752209

Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid (ERN) 2 g/day for 8 weeks
Number of subjects: 8
Study: 26040944

Group type: EXPERIMENTAL
Intervention: Lying-flat (0°) head positioning
Number of subjects: 16800

Group type: COMPARATOR
Intervention: Sitting-up (≥ 30°) head positioning
Number of subjects: 16800
Study: 23839169

Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM) analysis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tract-based spatial statistics (TBSS) analysis
Number of subjects: 50
Study: 21756364

Group type: EXPERIMENTAL
Intervention: High-dose pirfenidone (1800 mg/day)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Low-dose pirfenidone (1200 mg/day)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 18803561

Group type: EXPERIMENTAL
Intervention: Induced ventricular tachycardias (VTs)
Number of subjects: 72
Study: 16735334

Group type: EXPERIMENTAL
Intervention: Curtains treated with lambdacyhalothrin and water treatment with pyriproxyfen chips in Veracruz
Number of subjects: 10049

Group type: EXPERIMENTAL
Intervention: Curtains treated with longlasting deltamethrin (PermaNet) plus water jar covers in Trujillo
Number of subjects: 10049

Group type: COMPARATOR
Intervention: Control group in Veracruz
Number of subjects: 10049

Group type: COMPARATOR
Intervention: Control group in Trujillo
Number of subjects: 10049
Study: 15332694

Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for adverse drug events (ADEs)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for preventable ADEs
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for potential ADEs
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for life-threatening ADEs
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for serious ADEs
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for significant ADEs
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pharmacist surveillance for drug classes associated with ADEs
Number of subjects: 543
Study: 11319565

Group type: EXPERIMENTAL
Intervention: Third-person perspective
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-person perspective
Number of subjects: 0
Study: 9283534

Group type: EXPERIMENTAL
Intervention: Nocturnal CPAP plus optimal medical therapy (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Optimal medical therapy alone (n = 8)
Number of subjects: 17
Study: 8099549

Group type: EXPERIMENTAL
Intervention: esmolol 500 micrograms.kg‐1 over 1 min followed by 100 micrograms.kg‐1.min‐1
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 3324520

Group type: EXPERIMENTAL
Intervention: Febuprol (3 X 200 mg t. i. d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Febuprol
Number of subjects: 10
Study: 30587618

Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin split (GCsplit)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin (GCarbo)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gemcitabine/Cisplatin (GC)
Number of subjects: 41
Study: 28862770

Group type: EXPERIMENTAL
Intervention: Oral glucosamine (GS) + hyaluronic acid (HA) injection
Number of subjects: 136

Group type: COMPARATOR
Intervention: Oral placebo + hyaluronic acid (HA) injection
Number of subjects: 136
Study: 26777773

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) as an adjunct to usual care (medication)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care (medication)
Number of subjects: 248
Study: 24655729

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 22553931

Group type: EXPERIMENTAL
Intervention: l-arginine (6.4 g/day)
Number of subjects: 144
Study: 19820079

Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 2210

Group type: COMPARATOR
Intervention: Passive household smoke exposure
Number of subjects: 2210
Study: 18008242

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (SP; 250 and 12.5 mg)
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1189
Study: 16166818

Group type: EXPERIMENTAL
Intervention: 300 ml wine from one of four different grapes and fermentation processes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 60
Study: 14566165

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 10907623

Group type: EXPERIMENTAL
Intervention: 900 mg magnesium citrate twice daily for 1 month
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 45
Study: 8876343

Group type: EXPERIMENTAL
Intervention: Gainers Fuel 1000 (GF)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phosphagain (P)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maltodextrin (M)
Number of subjects: 28
Study: 10147952

Group type: EXPERIMENTAL
Intervention: Right-heart catheterization (RHC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No right-heart catheterization (no RHC)
Number of subjects: 33
Study: 6208750

Group type: EXPERIMENTAL
Intervention: Infradiaphragmatic irradiation
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cis-platinum, bleomycin, and vinblastine)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus irradiation
Number of subjects: 196
Study: 3946806

Group type: EXPERIMENTAL
Intervention: Naloxone 5 micrograms X kg‐1 X h‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Naloxone 10 micrograms X kg‐1 X h‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 45
Study: 30120775

Group type: EXPERIMENTAL
Intervention: Continuous FHR monitoring
Number of subjects: 2652

Group type: COMPARATOR
Intervention: Intermittent FHR monitoring
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Both monitoring methods
Number of subjects: 2652
Study: 28143529

Group type: EXPERIMENTAL
Intervention: Individualized, computerized patient decision-aid for immunosuppressive drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pamphlet with information about lupus and its treatment
Number of subjects: 0
Study: 25932553

Group type: EXPERIMENTAL
Intervention: Emixustat (2, 5, 7, or 10 mg once daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Emixustat
Number of subjects: 72
Study: 23545911

Group type: EXPERIMENTAL
Intervention: Extended-release 45 mg oral minocycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release 45 mg oral minocycline plus 15% azelaic acid
Number of subjects: 0
Study: 20503462

Group type: EXPERIMENTAL
Intervention: Ear acupressure intervention with seed embedding for 15 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 18226251

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid use
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: COPD (former smokers)
Number of subjects: 35
Study: 16413877

Group type: EXPERIMENTAL
Intervention: Iron (12.5 mg) and folic acid (50 mug)
Number of subjects: 24076

Group type: EXPERIMENTAL
Intervention: Iron, folic acid, and zinc
Number of subjects: 24076

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24076
Study: 12409968

Group type: EXPERIMENTAL
Intervention: MCG QRS‐T area integrals and QRS‐T angle in magnetic field maps
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: QRS‐T integral 16000 fT.s
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional 12-lead electrocardiographic (ECG) LVH indices (Sokolow‐Lyon voltage, Cornell voltage, Cornell voltage duration product)
Number of subjects: 42
Study: 9825256

Group type: EXPERIMENTAL
Intervention: New topical therapies
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: New treatments that control IOP effectively over time
Number of subjects: 200
Study: 7907677

Group type: EXPERIMENTAL
Intervention: Warfarin (prothrombin time ratio 1.3‐1.8, international normalised ratio 2.0‐4.5)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Aspirin 325 mg daily
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1100
Study: 2811069

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg) administered twice daily for five days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bumetanide (1 mg, i.v.) administered for the last three days of each period
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administered twice daily for five days
Number of subjects: 8
Study: 4037

Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline sulfate (beta‐adrenoceptor stimulating compound)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study: 29752828

Group type: EXPERIMENTAL
Intervention: Cigarettes containing 20 mg of THC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Driving simulation conditions
Number of subjects: 0
Study: 27032659

Group type: EXPERIMENTAL
Intervention: BREATHE (Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Person-centered treatment planning (Control)
Number of subjects: 145
Study: 24365986

Group type: EXPERIMENTAL
Intervention: Tac (twice-daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TacMR (once-daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tac (twice-daily) after switching back
Number of subjects: 20
Study: 22375890

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (16% MUFA and 8% SFA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: SFA-rich diet (16% SFA and 8% MUFA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 17
Study: 20584695

Group type: EXPERIMENTAL
Intervention: Self-prescribed decoction eliminating herpes combined with recombinant IL-2 and valaciclovir hydrochloride tablets
Number of subjects: 140

Group type: COMPARATOR
Intervention: Recombinant IL-2 and valaciclovir hydrochloride tablets
Number of subjects: 140
Study: 18676527

Group type: EXPERIMENTAL
Intervention: Standard dose of American ginseng extract
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low dose of American ginseng extract
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15811052

Group type: EXPERIMENTAL
Intervention: Cybersonic
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Braun 3D Excel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Manual toothbrush (Elmex super 29)
Number of subjects: 120
Study: 12971959

Group type: EXPERIMENTAL
Intervention: Prophylactic therapy (specifics not detailed)
Number of subjects: 314

Group type: COMPARATOR
Intervention: No prophylactic therapy (control group)
Number of subjects: 314
Study: 10395842

Group type: EXPERIMENTAL
Intervention: Canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canarypox vaccine expressing multiple HIV-1 genes given with rgp120
Number of subjects: 0
Study: 8618110

Group type: EXPERIMENTAL
Intervention: Cefetamet-pivoxil (CET, 500 mg BID)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefixime (CFX, 400 mg qD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefuroxime axetil (CA, 250 mg BID)
Number of subjects: 24
Study: 2405523

Group type: EXPERIMENTAL
Intervention: Cefmetazole (CM) 1 gram IV every 8 hours for 3 doses starting 30 minutes before surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cefoxitin (CX) 2 grams IV every 6 hours for 3 doses
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cefmetazole (CM)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cefoxitin (CX)
Number of subjects: 78
Study: 116287

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 12
Study: 29609113

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin/D-mannitol study product
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (without glycyrrhizin/D-mannitol)
Number of subjects: 25
Study: 27549811

Group type: EXPERIMENTAL
Intervention: Prescribed exercise
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined exercise and CBT
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 44
Study: 24458748

Group type: EXPERIMENTAL
Intervention: Post-space flight skin sensitivity measurement at 250 Hz at the heel for hypersensitive astronauts (n = 6)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-space flight computerized dynamic posturography (CDP) equilibrium (EQ) scores for hypersensitive astronauts (n = 6)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pre- and post-space flight skin sensitivity measurement at 3 and 25 Hz on the great toe
Number of subjects: 11
Study: 23110444

Group type: EXPERIMENTAL
Intervention: Ibuprofen foam dressing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparator foam dressing without ibuprofen
Number of subjects: 120
Study: 20504911

Group type: EXPERIMENTAL
Intervention: Valsartan (240 to 320 mg.day(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bradykinin B2-type receptor antagonist icatibant (50 mug.kg(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17646507

Group type: EXPERIMENTAL
Intervention: Liberal fluid management (median 4250 mL, range 3150-5200 mL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Restrictive fluid management (median 1740 mL, range 1100-2165 mL)
Number of subjects: 48
Study: 15810473

Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction Vitalizer toothbrush
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral-B CrossAction toothbrush
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral-B Advantage toothbrush
Number of subjects: 50

Group type: COMPARATOR
Intervention: Crest SpinBrush Pro brush
Number of subjects: 50
Study: 12003176

Group type: EXPERIMENTAL
Intervention: Monocyte apheresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 30
Study: 10098823

Group type: EXPERIMENTAL
Intervention: Comprehensive behaviorally oriented program for lifestyle change
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 8732114

Group type: EXPERIMENTAL
Intervention: Intracavitary microwave hyperthermia combined with external irradiation (R + H)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Radiation (R) alone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intracavitary microwave hyperthermia with T90 >= 43 degrees C
Number of subjects: 125
Study: 1931398

Group type: EXPERIMENTAL
Intervention: Pindolol 4 micrograms kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pindolol 2 micrograms kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study: 6110088

Group type: EXPERIMENTAL
Intervention: Vaccine (3 monthly injections)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo (corresponding injections)
Number of subjects: 318
Study: 31924327

Group type: EXPERIMENTAL
Intervention: Body weight (BW) protocol (n=245)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Body surface area (BSA) protocol (n=244)
Number of subjects: 489
Study: 31794470

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymectomy plus prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 0
Study: 27807290

Group type: EXPERIMENTAL
Intervention: Novel scoring system
Number of subjects: 111

Group type: COMPARATOR
Intervention: Eichenholtz system
Number of subjects: 111

Group type: COMPARATOR
Intervention: Schon system
Number of subjects: 111
Study: 26368296

Group type: EXPERIMENTAL
Intervention: Mesalamine granules 1.5 g once daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24418672

Group type: EXPERIMENTAL
Intervention: Upper body resistance exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lower body resistance exercise
Number of subjects: 11